Global Health Economics and Outcomes Resource (HEOR) Industry Report: Analysis and Forecast 2022-2027
Health Economics and Outcomes Resource (HEOR) Industry Report by Regional Category Spend, Price Analysis, Key Demand, and Price Indicators, and Best Buying Practices
In 2021, the global HEOR market was worth USD 1364.3 million. During the period of 2022 and 2027, the sector is projected to expand at an 11.14 percent CAGR, reaching a value of approximately USD 2779.2 million.
A skilled labour shortage caused by investments in technology and infrastructure is predicted to boost HEOR levels in 2021-22. While personnel, overheads, software, and databases are the important price indicators, North America is the main demand indicator and the highest category spender by area.
HEOR: Industry Definition and Segmentation
Scope:
The Health Economics and Outcomes Resource is a department within a life science or pharmaceutical firm that provides indications and proofs of the worth of a recent medicine or drug, as well as other interventions for compensation and health care spenders.
Get a Free Sample Report with Table of Contents: – https://www.procurementresource.com/reports/heor-service-industry-report/request-sample
The HEOR service industry report comprises of segments based on applications such as:
- Drug application includes developing drugs and approved drugs.
- Service applications include real-world evidence, payer evidence, pricing and reimbursement, epidemiology studies, and market access.
- Offering applications are outsourced and in-house.
- End-use includes healthcare providers, government organizations, biotech and pharma companies, and healthcare payers.
Snapshot of the Report
HEOR services outlook consists of Industry segmentation: Impact forces, key drivers, development, competitive structure, challenges. HEOR by application is divided into the market by drug, market by service, market by offering, market by end-use.
Read Full Report with Table of Contents: – https://www.procurementresource.com/reports/heor-service-industry-report
The regional markets for the industry can be divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Category Drivers
Mandatory HTA submission requirements primarily drive the HEOR market, and the growing impact of real-world evidence in P&R. Pharmaceutical companies are being forced to expand beyond their comfort zones, such as employing big data analytics and m-health technologies, which is driving a lot of outsourcing. In addition, cost-cutting in the pharmaceutical industry has led to a rise in outsourcing these services without increasing headcount.
The HEOR procurement is affected by the lacking experience with genetics and defining sub-group populations to demonstrate effective outcomes. Furthermore, there is a lack of standardization in the HTA requirements.
Category Insight by Region
North America is predicted to carry an essential share over the forecast period registering the fastest growth within the HEOR market. North America and Europe will have a moderate regional supply, capacity addition, and buyer power, whereas Asia will have moderate regional supply and buyer power and low-capacity expansion. Availability of digital platforms and data analytics, demand from payers and HTA bodies in North America and Europe is higher than in Asia.
HEOR Billing
Clinical service billing rate varies depending on the project and the client’s needs. The billing rates are influenced by client-related parameters such as client size and type (pharma/biotech), the client spends on specific clinical categories, the complexity of services/procedures, length of engagement, etc. Apart from Client- related factors, supplier and market-related factors also influence the HEOR billing like for supplier-related factors, type of suppliers engaged: CRO/ technology providers/specialists; Availability of clinical unit, facility, equipment; technology investment; partnership with other firms like hospitals, patient recruitment organizations, technology providers.
Market-related factors like new technologies in the clinical sector; regulatory compliance, inflation, compliance to new regulation/industry guidance by FDA/WHO/CDC.
Demand/Supply Overview
Due to a shift in clinical trials to these regions, availability of patient pool, lower FTE rate, and rapid technology integration by suppliers, the move to virtual has exacerbated demand in developed economies. However, the APAC region will see moderate demand due to shifting clinical trials to these regions, availability of patient pool, lower FTE rate, and rapid technology integration by suppliers. Most HEOR is outsourced to global players (consultants or CROs), who then hire specialized players as needed. Fee-for-service and T&M are the most common pricing words in this category. As the market consolidates, the sector is moving toward strategic alliances with end-to-end service providers. For example, in the early stages of a project, it may be necessary to hire specialty consultants on a day-rate basis to gather preliminary data for candidate selection. As a result of supplier base consolidation, pharma companies will form strategic agreements with full-service HEOR providers rather than sub-category experts in the future.
Best Procurement Practices
The global HEOR industry report by Procurement Resource gives an in-depth analysis of the best buying practices followed by the major consumers of HEOR across the globe, such as engagement models, sourcing strategy, pricing model, contract model, technology strategy, governance model, and order management.
Category Management Studies
The necessity to evaluate the market for potential and effective product pricing is increasing due to an increase in the number of pharmaceuticals in large pharma product pipelines and the desire for orphan drugs to address unmet medical requirements of patients. In addition, the entry of disruptive technologies, such as big data analytics and m-health, is expected to increase in the future, as more HTA organizations around the world require real-world evidence. As a result, the market is expected to grow further, primarily due to the increasing requirement of evidence-based approaches to demonstrate the value of the drug.
Key Supplier Profiles included in the Global Health Economics and Outcomes Resource (HEOR) Industry Report
The major players in the market are IQVIA, Medpace, Convance, Syneos Health, McKesson Corporation. The report covers capacity additions, investments, mergers and acquisitions, and other latest developments of the suppliers.
About Us:
Procurement Resource ensures that our clients remain at the vanguard of their industries by providing actionable procurement intelligence with the help of our expert analysts, researchers, and domain experts. Our team of highly seasoned analysts undertake extensive research to provide our customers with the latest and up-to-date market reports, cost-models, price analysis, benchmarking, and category insights, which aid in simplifying the procurement process for our clientele. We work with a diverse range of procurement teams across industries to get real-time data and insights that can be effectively implemented by our customers. We also track the prices and production costs of an extensive range of goods and commodities, thus, providing you with the updated and reliable data. We, at Procurement Resource, with the help of the latest and cutting-edge techniques in the industry, help our clients understand the supply chain, procurement, and industry climate, so that they can form strategies which ensure their optimum growth.
Contact Us:
Company Name: Procurement Resource
Contact Person: Chris Smiths
Email: sales@procurementresource.com
Toll Free Number: USA & Canada: +1-415-325-5166 | Europe & Africa: +44-702-402-5790 | APAC: +91-8586081494
Address: 30 North Gould Street, Sheridan, WY 82801, USA
City: Sheridan
State: Wyoming
Country: United States
Website: https://www.procurementresource.com/
